Advertisement

Acta Neuropathologica

, Volume 127, Issue 4, pp 617–618 | Cite as

Amyloid and tau in the brain in sporadic Alzheimer’s disease: defining the chicken and the egg

  • Cheryl A. Hawkes
  • Roxana O. CarareEmail author
  • Roy O. Weller
Open Access
Correspondence

Keywords

Dementia Cerebral Artery Brain Parenchyma Cerebral Amyloid Angiopathy Vascular Basement Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

In the October 2013 issue of Acta Neuropathologica there were three very interesting articles on: Amyloid or tau: the chicken or the egg? In the first article, David Mann and John Hardy [10] argued that the deposition of aggregated amyloid β (Aβ) protein in the brain is a primary driving force behind the pathogenesis of Alzheimer’s disease with tau pathology following as a consequential or at least a secondary event. In the communication that followed, Braak and Del Tredici [3] presented the contrary argument with accumulation of tau protein as the primary event in sporadic Alzheimer’s disease. Attems and Jellinger [2] questioned the concept of a chicken and egg and suggested that the majority of cases of age-associated dementia are not caused by one single primary pathological mechanism.

Many of the arguments put forward in these three contributions rely on observations derived from human brain material. Although human brain specimens have been essential for defining the diagnosis of Alzheimer’s disease and other dementias and for identifying some of the problems associated with those dementias, the study of human material is not necessarily the best and sole way of solving the “chicken and egg” problem. It is tacitly assumed that the primary problems lie with the deposition of insoluble Aβ as plaques in the brain, or the toxicity of soluble Aβ, or with the accumulation of hyperphosphorylated tau in neurons and neurites. But, have we identified the egg? What is the primary problem? In order to answer this question we should perhaps review the changes that occur in the brain with age and how they affect the pathophysiology of the brain and result in dementia.

One example of this approach would be to consider the major risk factors for sporadic Alzheimer’s disease viz: age and possession of the ε4 allele of apolipoprotein E (APOE4), and take the lead from observations in human brains to ask the questions “Why does Aβ accumulate in the brain with age?” “What are the pathophysiological consequences for the brain of the accumulation of Aβ in the walls of cerebral arteries and in brain parenchyma?” It is clear from the study of human brains that there is an age-related failure of elimination of Aβ. Experimental studies and observations in human brains suggest that various pathways for the elimination of Aβ from the brain fail with age. Those pathways include degradation by neprilysin [11] and other enzymes and absorption of Aβ into the blood [13, 19]. In addition, there is an age-related failure of elimination of Aβ along the perivascular drainage pathways [7] that serve as lymphatic drainage pathways for interstitial fluid and solutes (including Aβ) from the brain [4, 5, 17]. Impaired elimination of Aβ along perivascular drainage pathways is further accentuated in the presence of APOE4 [8]. Hallmarks of such failure are the deposition of Aβ aggregates in the walls of arteries as cerebral amyloid angiopathy (CAA) and as plaques of Aβ in the brain parenchyma; there is also a rise in the level of soluble Aβ in the brain in Alzheimer’s disease [9, 15] and the accumulation of fluid in subcortical white matter as leukoaraiosis [12]. The significance of CAA has been emphasised in human and experimental studies which showed that severe CAA was strongly related to the presence of dementia [6, 18].

Two major causes of age-related failure of perivascular elimination of Aβ from the brain have been identified, first: the progressive stiffening that occurs in the walls of cerebral arteries with age [16]; second: the changes that occur in basement membranes with age [7]. Theoretical models suggest that the contrary wave that follows the pulse wave along cerebral arteries is a major motive force for perivascular drainage of Aβ from the brain [14]. According to this model, stiffening of cerebral arteries would reduce the amplitude of pulsations and thus reduce the motive force for drainage of Aβ. This is supported by experimental studies showing that a reduction in arterial pulsations impedes perivascular drainage [1]. Age-related changes in vascular basement membranes that are the pathways for perivascular drainage and in their component proteins have been detected in human cerebral arteries (see [7]); in mice such changes are associated with demonstrably impaired perivascular drainage [7]. Impairment and slowing of perivascular drainage is associated with the formation of fibrillar amyloid in the walls of cerebral vessels as CAA which further impedes perivascular drainage of Aβ [7]. Stiffening of cerebral artery walls and age-related changes in basement membranes appear to be universal factors in the failure of perivascular elimination of Aβ from the ageing brain and in Alzheimer’s disease.

What, therefore, is the egg? Age-changes in the walls of cerebral arteries that impair the drainage of soluble Aβ could well be a prime candidate [7]. The chicken that develops from this egg may be the accumulation of insoluble aggregates of Aβ as CAA and as plaques in the brain but it could also be loss of homoeostasis of the neuronal environment due to failure of elimination of a range of soluble metabolites from the brain parenchyma.

We have emphasised here that, despite the importance of studying the distribution of Aβ and tau in human post-mortem brain in dementias such as Alzheimer’s disease, it is equally important to consider the wider pathophysiological effects of ageing of cerebral arteries on the brain in relation to Alzheimer’s disease. Such changes may lead not only to the accumulation of Aβ in the brain and artery walls but also to loss of homoeostasis of the neuronal environment and disturbance of neuronal function that may be related to dementia. Facilitation of elimination of soluble Aβ and other metabolites from the brain along the walls of ageing arteries could be a fruitful therapeutic strategy for the prevention and management of Alzheimer’s disease [5].

Notes

Acknowledgments

The work discussed here is derived from projects funded by the Biotechnology and Biological Sciences Research Council UK and by Alzheimer’s Research UK.

References

  1. 1.
    Arbel-Ornath M, Hudry E, Eikermann-Haerter K, Hou S, Gregory JL, Zhao L, Betensky RA, Frosch MP, Greenberg SM, Bacskai BJ (2013) Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer’s disease mouse models. Acta Neuropathol 126(3):353–364. doi: 10.1007/s00401-013-1145-2 PubMedCrossRefGoogle Scholar
  2. 2.
    Attems J, Jellinger KA (2013) Amyloid and tau: neither chicken nor egg but two partners in crime! Acta Neuropathol 126(4):619–621. doi: 10.1007/s00401-013-1167-9 PubMedCrossRefGoogle Scholar
  3. 3.
    Braak H, Del Tredici K (2013) Reply: the early pathological process in sporadic Alzheimer’s disease. Acta Neuropathol 126(4):615–618. doi: 10.1007/s00401-013-1170-1 PubMedCrossRefGoogle Scholar
  4. 4.
    Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JAR, Perry VH, Weller RO (2008) Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries. Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 34:131–144PubMedCrossRefGoogle Scholar
  5. 5.
    Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO (2013) Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 39(6):593–611. doi: 10.1111/nan.12042 PubMedCrossRefGoogle Scholar
  6. 6.
    CFAS NGoM (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357:169–175CrossRefGoogle Scholar
  7. 7.
    Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 121:431–443. doi: 10.1007/s00401-011-0801-7 PubMedCrossRefGoogle Scholar
  8. 8.
    Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO (2012) Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE epsilon4 allele. PLoS ONE 7(7):e41636. doi: 10.1371/journal.pone.0041636 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155(3):853–862PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mann DM, Hardy J (2013) Amyloid or tau: the chicken or the egg? Acta Neuropathol 126(4):609–613. doi: 10.1007/s00401-013-1162-1 PubMedCrossRefGoogle Scholar
  11. 11.
    Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG (2006) Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65:1012–1021PubMedCrossRefGoogle Scholar
  12. 12.
    Roher AE, Kuo Y-M, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA (2003) Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med 9:112–122PubMedCentralPubMedGoogle Scholar
  13. 13.
    Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harbor Perspect Med 2(10). doi: 10.1101/cshperspect.a011452
  14. 14.
    Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO (2006) Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 238:962–974PubMedCrossRefGoogle Scholar
  15. 15.
    van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Oligomeric Abeta in Alzheimer’s disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20(2):468–480. doi: 10.1111/j.1750-3639.2009.00321.x PubMedCrossRefGoogle Scholar
  16. 16.
    Weller RO, Boche D, Nicoll JA (2009) Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 118:87–102PubMedCrossRefGoogle Scholar
  17. 17.
    Weller RO, Djuanda E, Yow HY, Carare RO (2009) Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117:1–14PubMedCrossRefGoogle Scholar
  18. 18.
    Xu W, Xu F, Anderson ME, Kotarba AE, Davis J, Robinson JK, Van Nostrand WE (2014) Cerebral microvascular rather than parenchymal amyloid-beta protein pathology promotes early cognitive impairment in transgenic mice. J Alzheimer’s Disease 38(3):621–632. doi: 10.3233/JAD-130758 Google Scholar
  19. 19.
    Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89:807–811PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Cheryl A. Hawkes
    • 1
  • Roxana O. Carare
    • 1
    Email author
  • Roy O. Weller
    • 1
  1. 1.Faculty of Medicine, Institute for Life SciencesUniversity of SouthamptonSouthamptonUK

Personalised recommendations